Frazer welcomes Federal Government decision on Gardasil

December 06, 2006

The vaccine prevents four of dozens of strains of the human papillomavirus (HPV) which cause genital warts and cervical cancer.

The vaccine is distributed in Australia and New Zealand by Melbourne-based pharmaceutical manufacturer CSL and distributed worldwide by US drugmaker Merck & Co.

Professor Frazer and his late research partner, Dr Jian Zhou, helped create the vaccine.

The Federal Government has announced Gardasil® will be available on an ongoing basis for 12 to 13-year-old girls to be delivered through schools from as early as April next year. The Government will also fund a two-year catch-up programme for 13 to 18-year-old girls in schools and 18 to 26-year-old women to be delivered through GPs.

"I'm delighted the Federal Government has decided to adopt the recommendation of the Pharmaceutical Benefits Advisory Committee (PBAC), to implement a comprehensive program for introduction of the HPV vaccine that Dr Jian Zhou and I helped develop to prevent cervical cancer," Professor Frazer said.

"I'm also pleased that the appropriate processes have been followed in reaching this decision. The Government's decision, combined with an ongoing cervical cancer-screening program, will be a significant step towards further reduction of cervical cancer risk for Australian women."

Cervical cancer kills about 270,000 women worldwide each year.

Research Australia

Related Cervical Cancer Articles from Brightsurf:

HPV strains may impact cervical cancer prognosis
An analysis of cervical cancers in Ugandan women has uncovered significant genomic differences between tumours caused by different strains of human papillomavirus (HPV), signifying HPV type may impact cervical cancer characteristics and prognosis.

American Cancer Society updates guideline for cervical cancer screening
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

Disasters can affect cervical cancer screening for years
Screening is important for the early detection of cervical cancer, but rates were significantly affected, in some areas for years, following a devastating earthquake and tsunami in Japan.

Cervical cancer elimination possible within two decades in the US
At current levels of screening and HPV vaccination, cervical cancer incidence in the US is projected to fall below the threshold of elimination by 2038-2046.

Cervical cancer screening saves lives
Three-year interval in screening for cervical cancer is as effective as annual checkups, study finds.

Cervical cancer could be eliminated within a century
Cervical cancer could be eliminated worldwide as a public health issue within the next century.

25 years of learning to combat cervical cancer
A recent paper from the lab of Professor Sudhir Krishna at the National Centre for Biological Sciences, Bangalore, reviews the progress made in cervical cancer research over the past 25 years.

Cervical cancer screening numbers drop off in women 45-65
Virtually all cervical cancers are caused by HPV, and much of the attention in recent years has focused on preventing infections in younger women through HPV vaccination.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cost-effectiveness analysis of 12 cervical cancer screenings
This cost-effectiveness analysis incorporates women's preferences and estimates quality of life and economic outcomes for 12 cervical cancer screening strategies.

Read More: Cervical Cancer News and Cervical Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to